These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7486634)

  • 1. A randomized, double-blind, placebo-controlled ascending dose tolerance study of 619C89 in acute stroke.
    Muir KW; Lees KR; Hamilton SJ; George CF; Hobbiger SF; Lunnon MW
    Ann N Y Acad Sci; 1995 Sep; 765():328-9. PubMed ID: 7486634
    [No Abstract]   [Full Text] [Related]  

  • 2. The tolerability, pharmacokinetics and pharmacodynamics of increasing intravenous doses of 619C89, a novel compound for the acute treatment of stroke, in healthy volunteers.
    Mercer AJ; Lamb RJ; Hussein Z; Hobbiger S; Posner J
    Ann N Y Acad Sci; 1995 Sep; 765():324-6. PubMed ID: 7486632
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions.
    Hussein Z; Fraser IJ; Lees KR; Muir KW; Lunnon MW; Hobbiger SF; Posner J
    Br J Clin Pharmacol; 1996 Jun; 41(6):505-11. PubMed ID: 8799514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke.
    Muir KW; Lees KR
    Ann N Y Acad Sci; 1995 Sep; 765():315-6. PubMed ID: 7486627
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and tolerability of 619C89 after acute stroke.
    Muir KW; Hamilton SJ; Lunnon MW; Hobbiger S; Lees KR
    Cerebrovasc Dis; 1998; 8(1):31-7. PubMed ID: 9645979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke.
    Muir KW; Holzapfel L; Lees KR
    Cerebrovasc Dis; 2000; 10(6):431-6. PubMed ID: 11070372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does neuroprotection improve stroke outcome?
    Lees KR
    Lancet; 1998 May; 351(9114):1447-8. PubMed ID: 9605797
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and tolerability of lifarizine in acute ischemic stroke. A pilot study. Lifarizine Study Group.
    Squire IB; Lees KR; Pryse-Phillips W; Kertesz A; Bamford J
    Ann N Y Acad Sci; 1995 Sep; 765():317-8. PubMed ID: 7486628
    [No Abstract]   [Full Text] [Related]  

  • 9. Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia.
    Milojkovic D; Short K; Salisbury JR; Creamer D; du Vivier AW; Mufti GJ
    Leukemia; 2003 Jul; 17(7):1414-6. PubMed ID: 12835733
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical pharmacology of CNS 1102 in man.
    Muir KW; Grosset DG; Lees KR
    Ann N Y Acad Sci; 1995 Sep; 765():336-7. PubMed ID: 7486638
    [No Abstract]   [Full Text] [Related]  

  • 11. [About cavinton therapy of the patients with brain vascular diseases].
    Nikitina VV; Pravdina AN; Zapatrina OV
    Voen Med Zh; 2007 Feb; 328(2):43-5. PubMed ID: 17508611
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group.
    Lacourcière Y; Pool JL; Svetkey L; Gradman AH; Larochelle P; de Champlain J; Smith WB
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):454-61. PubMed ID: 9607384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteplase for thrombolysis in acute ischemic stroke.
    Med Lett Drugs Ther; 1996 Nov; 38(987):99-100. PubMed ID: 8914507
    [No Abstract]   [Full Text] [Related]  

  • 14. [Long-term medical treatment of acute cerebrovascular disease sequelae (comparison papaverine-piribedil].
    Piccinelli A; Neri G; Agnoli A
    Minerva Med; 1974 Nov; 65(80):4199-213. PubMed ID: 4610451
    [No Abstract]   [Full Text] [Related]  

  • 15. Using pathophysiology in acute stroke trials.
    Baird AE; Warach S
    Stroke; 1999 Jun; 30(6):1293. PubMed ID: 10356119
    [No Abstract]   [Full Text] [Related]  

  • 16. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group.
    Donnan GA; Davis SM; Chambers BR; Gates PC; Hankey GJ; McNeil JJ; Rosen D; Stewart-Wynne EG; Tuck RR
    JAMA; 1996 Sep; 276(12):961-6. PubMed ID: 8805730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).
    Hacke W; Kaste M; Fieschi C; Toni D; Lesaffre E; von Kummer R; Boysen G; Bluhmki E; Höxter G; Mahagne MH
    JAMA; 1995 Oct; 274(13):1017-25. PubMed ID: 7563451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Flunarizine in the therapy of chronic cerebrovascular insufficiency. Multicentric controlled study].
    Arrigo A; Lottici P; Alfonsi E; Terraneo GB
    Clin Ter; 1984 Sep; 110(6):541-8. PubMed ID: 6238768
    [No Abstract]   [Full Text] [Related]  

  • 19. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group.
    Diener HC
    Cerebrovasc Dis; 1998; 8(3):172-81. PubMed ID: 9619701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.